Mutated Actrt1 modulates neural circuit and results in schizophrenia in mouse
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus Musculus
SUBMITTER: 
Zhiheng Xu
PROVIDER: PXD071406 | iProX | Sat Nov 29 00:00:00 GMT 2025
REPOSITORIES: iProX
Similar Datasets
Project description:Disrupted circadian rhythms in a mouse model of schizophrenia
2012-03-01 | E-MEXP-3493 | biostudies-arrayexpress
Project description:A missense mutation (A391T) in the manganese transporter SLC39A8 is strongly associated with schizophrenia through GWAS, though the molecular connection to the brain remains hypothetical. Human carriers of A391T have reduced serum manganese, altered plasma glycosylation, and brain MRI changes consistent with altered metal transport. Here, using a mouse knock-in model homozygous for A391T, we show that the schizophrenia-associated variant changes protein glycosylation in the brain. N-linked glycosylation was most significantly impaired, with effects differing between regions. RNAseq analysis showed negligible variation, consistent with changes in the activity of glycosylation enzymes rather than gene expression. Finally, one third of all detected glycoproteins were differentially N-glycosylated in the cortex, including members of several pathways previously implicated in schizophrenia such as cell adhesion molecules and neurotransmitter receptors. These findings provide a mechanistic link between a risk allele and biochemical changes in the brain, furthering our molecular understanding of the pathophysiology of schizophrenia.
2022-03-08 | PXD021632 | Pride
Project description:Schizophrenia is a complex and severe neuropsychiatric disorder, with a wide range of debilitating symptoms. Several aspects of its multifactorial complexity are still unknown, and some are accepted to be an early developmental deficiency with a more specifically neurodevelopmental origin. Understanding timepoints of disturbances during neural cell differentiation processes could lead to an insight into the development of the disorder. In this context, human brain organoids and neural cells differentiated from patient-derived induced pluripotent stem cells are of great interest as a model to study the developmental origins of the disease. Here we evaluated the differential expression of proteins of schizophrenia patient-derived neural progenitors, early neurons, and brain organoids. Using bottom-up shotgun proteomics with a label-free approach for quantitative analysis. Multiple dysregulated proteins were found in pathways related to synapses, in line with postmortem tissue studies of schizophrenia patients. However, organoids and immature neurons exhibit impairments in pathways never before found in patient-derived induced pluripotent stem cell studies, such as spliceosomes and amino acid metabolism. In conclusion, here we provide comprehensive, large-scale, protein-level data that may uncover underlying mechanisms of the developmental origins of schizophrenia.
2023-03-11 | PXD026593 | Pride
Project description:Schizophrenia (SCZ) is a severe mental disorder with complex behavioral pathology and complex genetic risk. Here, we performed an integrated transcriptomic analysis of the prefrontal cortex in two distinct male C57BL/6 mouse models of schizophrenia, the neurodevelopmental methylazoxymethanol acetate (MAM) model and the acute non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist MK-801 model, compared to that of human patients. Transcriptome in the MK-801 model displayed a modest correlation with that of schizophrenia patients, higher than the MAM model, underscoring NMDAR antagonism's relevance to the core pathology of the disorder. Using weighted gene co-expression network analysis, we identified fifteen co-expression modules across the mouse models, with eight modules significantly associated with schizophrenia-like behavioral endophenotypes. Notably, modules darkturquoise (linked to hyperlocomotion) and royalblue (associated with social withdrawal) were enriched in Wnt and PI3K/Akt signaling pathways, respectively. Pharmacological inhibition of these two pathways specifically rectified corresponding behavioral anomalies in the MK-801 model, highlighting the critical role of altered Wnt and PI3K/Akt signaling in these behavioral domains of schizophrenia-related behaviors and proposing new avenues for therapeutic intervention.
2026-09-11 | GSE307928 | GEO
Project description:Schizophrenia is a neuropsychiatric syndrome characterized by the presence of psychotic, negative and cognitive symptoms. Cognitive deficits can appear even before the onset of the first psychotic episode and their severity has been recently associated with altered levels of small RNAs (sRNAs), including microRNAs. Nevertheless, how the dysregulation of sRNAs can lead to cognitive impairments and their role in the onset and pathophysiology of the disorder are still unknown. In our research, we hypothesized that hippocampal sRNAs generated in patients with schizophrenia could contribute to the impairment of specific cognitive domains that are altered in the disease. Through deep sequencing, we identified novel dysregulated sRNAs (including microRNAs and tRNA derived fragments) in the hippocampus of patients with schizophrenia. Furthermore, when injected in the hippocampus of wild-type mice, animals exhibited an impairment in spatial short-term memory accompanied by a reduction in spine density of CA1 pyramidal neurons. RNA-sequencing of the hippocampus of injected mice revealed changes in key pathways related to neurotransmission. Specifically, we found higher levels of the presynaptic marker for Parvalbumin interneurons synaptotagmin II (Syt2), mirroring observations made in the brain of schizophrenia patients. We also detected subtle morphological changes in mouse hippocampal microglia in response to sRNAs from affected individuals. Our results point out that sRNAs can contribute to cognitive symptoms in schizophrenia through synaptic alterations, highlighting these molecules as promising novel therapeutic targets for the disorder.
2026-07-29 | GSE325450 | GEO
Project description:Microglial RNA sequencing from humanized mouse model expressing schizophrenia susceptibility factor C4A
| PRJNA678711 | ENA
Project description:The study reports brain proteomic alterations in a chronic ketamine-induced mouse model of schizophrenia characterized by anxiety and cognitive impairment.
2022-09-15 | PXD036760 |
Project description:The neurodevelopmental theory of schizophrenia highlights the role of early brain development in the disorder's origins. Genome-wide association studies have linked schizophrenia to genetic variations in the AS3MT gene, particularly the AS3MTd2d3 isoform. To explore this connection, we created a transgenic mouse model (AS3MTd2d3-Tg) that expresses AS3MTd2d3 in cortical neural stem cells. These mice showed enlarged ventricles and impairments in sensorimotor gating and sociability. Single-cell and single-nucleus RNA sequencing of AS3MTd2d3-Tg brains revealed imbalances in cell fate and changes in excitatory neuron composition. AS3MTd2d3 was found to localize to the centrosome, disrupting mitotic spindle orientation and differentiation in the developing neocortex and organoids. Structural analysis indicated that exposed hydrophobic residues in AS3MTd2d3 are crucial for its pathogenic function. These findings may shed light on the early pathological features of schizophrenia.
2025-10-28 | PXD057242 | JPOST Repository
Project description:Large-scale genomic screenings greatly advanced our understanding of the genetic basis of schizophrenia. However, how this translates into neurobiological functioning is not clear. Therefore, we aimed to characterize the function of robust susceptibility gene zinc finger protein 804A (ZNF804A), using a model system of relevant cell type and neurodevelopmental timepoint. Based on previous findings, we hypothesized a role for ZNF804A in local protein translation. CRISPR/Cas9-mediated mutation of the risk gene led to increased synapse formation in human induced pluripotent stem cell (hiPSC)-derived developing glutamatergic forebrain neurons as assessed by high-content confocal imaging. Further, mass spectrometry analysis showed an increased recruitment of ribosomes to mutation neurites. Surface sensing of translation (SUnSET) screening complemented this by demonstrating an increased efficiency of local protein synthesis. Overall, these results introduce a novel cellular function for ZNF804A in a model system relevant to schizophrenia, uncovering some aspects of its neurobiology. Ultimately, findings of this study may aid to identify common mechanisms of susceptibility genes.
2026-03-31 | PXD047788 | Pride
Project description:Recent studies have identified presynaptic increase in striatal dopamine as the primary dopaminergic abnormality in schizophrenia, responsible for changes in cortical dopamine function in schizophrenic individuals. However, increased dopamine synthesis and release are not recapitulated in existing mouse models, limiting studies on disease progression and potential treatments. We found that the levels of glial cell line-derived neurotrophic factor (GDNF), a strong dopamine system modulator, are increased in the cerebrospinal fluid of first episode psychosis patients. Using a novel strategy to conditionally increase endogenous gene expression, we developed a mouse model with timed elevation of endogenous GDNF. Conditional ‘Knock Up’ of endogenous GDNF expression (GDNF cKU) in the central nervous system at midgestation resulted in an increase of dopamine levels in the presynaptic compartment of nigrostriatal dopamine neurons, hypodopaminergia in the prefrontal cortex (PFC) and schizophrenia-like behavioural deficits in the mouse. RNA sequencing from the PFC revealed gene expression changes similar to those previously found in schizophrenia patients, including downregulation of dopamine receptor 2 and adenosine A2a receptor (A2AR). Treatment of mice with A2AR antagonist istradefylline partially restored striatal and cortical dopamine levels, suggesting a potential therapeutic strategy to alleviate symptoms associated with schizophrenia. Taken together, our results demonstrate that timed increase in GDNF expression is sufficient to drive schizophrenia-like molecular and behavioural phenotypes, and represents a novel model for studying schizophrenia-associated pathologies in mice.
2023-01-03 | GSE162974 | GEO